PhilRedbeard (Talk | contribs) |
|||
Line 1: | Line 1: | ||
− | |||
− | |||
+ | {{Freiburg/CSS}} | ||
+ | {{Freiburg/Navbar}} | ||
+ | <html> | ||
+ | <head> | ||
+ | <link href="https://fonts.googleapis.com/css?family=Josefin+Sans:100" rel="stylesheet"> | ||
+ | <link rel="stylesheet" type="text/css" | ||
+ | href="https://2017.igem.org/Template:Team:Freiburg/CSS?action=raw&ctype=text/css"/> | ||
+ | <link rel="stylesheet" type="text/css" | ||
+ | href="https://2017.igem.org/Template:Team:Freiburg/CSS:bootstrap?action=raw&ctype=text/css"/> | ||
+ | <script type="text/javascript" src="https://2017.igem.org/Template:Team:Freiburg/JS:bootstrap?action=raw&ctype=text/javascript"></script> | ||
− | < | + | <style> |
− | + | font-family: 'Josefin Sans', serif; | |
+ | .item-tm { | ||
+ | background-color: white; | ||
+ | width:500; | ||
+ | height: auto; | ||
+ | margin: 10px; | ||
+ | overflow: hidden; | ||
+ | } | ||
+ | .item-tm p{ | ||
+ | font-family: 'Roboto', sans-serif!important; | ||
+ | font-size: 18px!important; | ||
+ | overflow: visible; | ||
+ | } | ||
+ | p.italic { | ||
+ | font-family: 'Roboto', sans-serif; | ||
+ | font-style: italic; | ||
+ | font-weight: 300; | ||
+ | } | ||
+ | pfeil{ | ||
+ | text-align: center; | ||
+ | color: black; | ||
+ | } | ||
+ | </style> | ||
+ | </head> | ||
+ | |||
+ | </div> | ||
</div> | </div> | ||
− | <div class=" | + | <body> |
− | + | <div class="container"> | |
+ | <div class="row"> | ||
+ | <div class="col-md-12 text-center"> | ||
+ | <div class="flex-container"> | ||
+ | <h1 align="center">Description</h1> | ||
+ | <div class="item-tm"> | ||
+ | <br> | ||
+ | <p> | ||
<p> | <p> | ||
The treatment and understanding of cancer is a challenging issue. New | The treatment and understanding of cancer is a challenging issue. New | ||
Line 35: | Line 75: | ||
and provide safer cancer cell-based immunotherapy. | and provide safer cancer cell-based immunotherapy. | ||
</p> | </p> | ||
+ | </p> | ||
+ | </div> | ||
+ | |||
+ | |||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | </body> | ||
</html> | </html> | ||
+ | |||
+ | {{Freiburg/Footer}} |
Latest revision as of 13:17, 13 October 2017
Description
The treatment and understanding of cancer is a challenging issue. New approaches like the chimeric antigen receptor (CAR) T-cells showed promising results in fighting cancer by enhancing the killing effects of cytotoxic T-cells. The main benefit of CAR T-cells is their high affinity to tumor antigens, however this raises the issue of possible off-target effects since tumor antigens are not solely expressed on tumor cells but also on healthy tissues (Fesnak et al. 2016; Morgan et al. 2010).
In order to avoid off-target effects, we aim to establish CAR T-cell lines which are only activated in the specific tumor microenvironment (Hanahan, Coussens 2012). The T-cells are modified to express CAR controlled by a genetic AND-gate system which needs two inputs from the tumor microenvironment to be activated. This would allow a highly localization restricted binding of cytotoxic T-cells to tumor cells and provide safer cancer cell-based immunotherapy.